eligibility_summary
Eligibility: Adults 18–75 with confirmed solid tumors after standard therapy failure/refusal, ECOG 0–2, survival >3 mo, able to consent/comply, contraception if childbearing. Exclude: immunotherapy <3 mo or chemo/radiation/surgery <1 mo, need for immunosuppression, other active cancer, inadequate counts or organ function, coagulopathy, active infection, HBV/HCV/HIV/CMV/syphilis+, major comorbidity, pregnancy/lactation, other trial <1 mo, allergy, apheresis/venous access, investigator concern.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: Autologous tumor neoantigen‑specific T cells (NeoT), type: adoptive cellular immunotherapy (biological). Manufacturing: patient monocytes → antigen‑presenting cells (dendritic‑like) that ingest tumor tissue to present patient‑specific neoantigens, autologous T cells are primed/expanded ex vivo and infused IV (>1×10^9). Mechanism: TCR‑mediated recognition of tumor‑specific neoantigen peptides presented by MHC on cancer cells, triggering cytotoxic killing (perforin/granzyme) and cytokine release (e.g., IFN‑γ), with helper/memory T‑cell support. Targets: malignant cells in advanced solid tumors (ovarian, NSCLC, colorectal, others) expressing somatic‑mutation neoantigens. Key pathways/cells: antigen processing/presentation (MHC I/II), TCR signaling, CD8+ CTL effector functions and apoptosis pathways. Design: single‑arm, Early Phase 1, IV infusion to assess safety, activity, and immunologic effects.